News

Filter News By

Clear Filters

  1. Cystic Fibrosis Foundation Is Exploring New CFTR Modulators

    October 24, 2019

    The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.

  2. CF Foundation Celebrates FDA Approval of Triple Combination

    October 21, 2019

    The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.

  3. Enterprise Therapeutics Awarded Up to $7M to Develop Mucus-Clearance Drug for People With CF

    October 15, 2019

    The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.

    Topics:

  4. Foundation Funds Early Stage Clinical Trial of a Potential Nonsense Mutation Treatment

    September 23, 2019

    The Cystic Fibrosis Foundation awarded up to $1.61 million to Eloxx Pharmaceuticals Inc. to conduct a U.S.-based Phase 2 clinical trial of an investigational drug that could potentially treat people with cystic fibrosis who have a nonsense mutation.

    Topics:

  5. ICER Announces Assessment of Triple-Combination Therapy

    September 13, 2019

    The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The first opportunity to comment runs through Sept. 25.

    Topics:

  6. The CF Foundation Awards Arcturus Therapeutics Up to $15M for RNA Therapy

    August 5, 2019

    The Cystic Fibrosis Foundation has increased its award to Arcturus Therapeutics to up to $15 million to develop a mutation-agnostic therapy for people with cystic fibrosis.
More Posts View All Posts

Related Content

Follow Us On